20/20 HealthCare Partners

20/20 HealthCare Partners LLC is a global investment group based in Auburndale, Massachusetts, specializing in the earliest stages of technology and life science innovation. The company focuses on investing in firms across various sectors, including diagnostic imaging, medical devices, healthcare technology, biotechnology, and pharmaceuticals. With a commitment to creating value, 20/20 HealthCare Partners collaborates with entrepreneurs, executives, and strategic partners within the healthcare community. The firm provides strategic advice, team building, product development, and syndicated investment to assist its partners in developing valuable companies that aim to enhance healthcare and improve quality of life.

Hillel Bachrach

Owner, Founder and Managing Partner

13 past transactions

Variantyx

Venture Round in 2023
Variantyx Inc. is a biotechnology company headquartered in Framingham, Massachusetts, that specializes in whole genome sequencing-based diagnostic testing. Founded in 2014, the company offers a comprehensive platform that includes its Genomic Unity® test, which identifies and reports all major types of genetic variants from a single patient sample. This test is designed to diagnose rare inherited disorders, providing a more efficient alternative to traditional genetic testing methods. Variantyx's technology enables hospitals and commercial laboratories to accurately analyze whole genome sequenced data, facilitating a better understanding of a patient's genetic makeup and leading to optimized treatment recommendations. The company's focus on genomic intelligence positions it at the forefront of precision medicine.

Variantyx

Series C in 2022
Variantyx Inc. is a biotechnology company headquartered in Framingham, Massachusetts, that specializes in whole genome sequencing-based diagnostic testing. Founded in 2014, the company offers a comprehensive platform that includes its Genomic Unity® test, which identifies and reports all major types of genetic variants from a single patient sample. This test is designed to diagnose rare inherited disorders, providing a more efficient alternative to traditional genetic testing methods. Variantyx's technology enables hospitals and commercial laboratories to accurately analyze whole genome sequenced data, facilitating a better understanding of a patient's genetic makeup and leading to optimized treatment recommendations. The company's focus on genomic intelligence positions it at the forefront of precision medicine.

Variantyx

Series C in 2021
Variantyx Inc. is a biotechnology company headquartered in Framingham, Massachusetts, that specializes in whole genome sequencing-based diagnostic testing. Founded in 2014, the company offers a comprehensive platform that includes its Genomic Unity® test, which identifies and reports all major types of genetic variants from a single patient sample. This test is designed to diagnose rare inherited disorders, providing a more efficient alternative to traditional genetic testing methods. Variantyx's technology enables hospitals and commercial laboratories to accurately analyze whole genome sequenced data, facilitating a better understanding of a patient's genetic makeup and leading to optimized treatment recommendations. The company's focus on genomic intelligence positions it at the forefront of precision medicine.

Coagulo Medical Technologies

Venture Round in 2020
Coagulo Medical Technologies, based in Auburndale, Massachusetts, specializes in developing innovative point-of-care testing platforms for managing coagulation disorders. Their portable and connected precision-medicine system detects, identifies, and quantifies the effects of all anticoagulants in whole blood, providing healthcare providers with actionable results to improve patient outcomes.

XRHealth

Venture Round in 2020
XRHealth Ltd. is a medical technology company based in Tel Aviv, Israel, that specializes in developing virtual reality (VR) software solutions for healthcare. Founded in 2016, the company offers an array of products designed to enhance patient care and treatment outcomes. Its offerings include VRPhysio, a platform for virtual physical therapy; VRReliever, which helps manage pain through distraction; VRCogni, aimed at improving motor function in stroke and dementia patients; and VRPsyc, which provides exposure therapy for various mental health disorders. Additionally, VRCoordi is designed to aid coordination recovery in patients with Parkinson's, brain injuries, and autism. By integrating immersive technologies with licensed clinicians and advanced data analytics, XRHealth provides comprehensive telehealth services, allowing patients to access treatment from the comfort of their own homes.

EnClear Therapies

Series A in 2020
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

Verseau Therapeutics

Venture Round in 2019
Verseau Therapeutics, Inc. is a biotechnology company focused on developing macrophage checkpoint modulators to address cancer, immune, and inflammatory diseases. Established in 2017 and headquartered in Lexington, Massachusetts, the company aims to create a new class of therapeutics that can modulate macrophage behavior. By identifying novel targets, Verseau's therapies are designed to facilitate a shift in macrophages from immune suppressors to activators, enhancing the effectiveness of immunotherapy for patients. Through this innovative approach, Verseau Therapeutics seeks to improve treatment outcomes for individuals suffering from various diseases.

SQZ Biotech

Series A in 2015
SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

EightSpokes

Venture Round in 2015
EightSpokes, Inc. is a software-as-a-service company based in Lexington, Massachusetts, established in 2012. It offers an intelligent cloud-based platform that enhances program and portfolio management specifically in the life sciences sector. The company's Enlighten launch management software addresses launch delays by replacing manual planning and coordination processes. Additionally, EightSpokes provides solutions for lifecycle management, mergers and acquisitions, and collaborative planning, facilitating synchronized execution across various teams. Its automation software builds a predictive engine that connects workflows among internal teams and external partners, optimizing the planning and forecasting stages of drug commercialization. By streamlining these processes, EightSpokes enables clients to reduce costs and accelerate the introduction of new medications to global markets.

PhysIQ

Venture Round in 2013
PhysIQ, Inc. is a health technology company based in Chicago, Illinois, that specializes in developing a cloud-based predictive platform for personalized physiology analytics. The company has created VitaLink, a remote patient monitoring interface that offers clinicians enhanced insights into the health status of chronically ill patients in an ambulatory setting. PhysIQ's technology processes various data streams to establish an individual's normal baseline, allowing for the monitoring and detection of clinically significant changes in health indicators. This capability enables healthcare providers to anticipate acute medical events before symptoms arise, while also empowering individuals to take control of their health and fitness. The platform is adaptable and can be integrated into patient monitoring devices from other manufacturers, distinguishing it from other technologies that rely on population-based statistics. PhysIQ was previously known as VGBio, Inc. and was incorporated in 2013.

QBotix

Series A in 2012
A solar panel that tracks the sun throughout the day produces up to 30% more electricity than one that does not. Solar project developers install single-axis tracking for most utility-scale sites, balancing upfront costs versus electricity revenues to maximize rates of return. QBotix disrupts today's cost curve of fixed-tilt, single-axis tracking, and dual-axis tracking with an innovative tracking solution that offers dual-axis tracking at single-axis price. This reduces the levelized cost of energy by 10-20% while providing the added benefit of higher reliability and system intelligence.

Velocomp

Venture Round in 2011
Velocomp LLC is a sports technology company based in Boca Raton, Florida, that specializes in power measurement tools for cyclists globally. Founded in 2006, the company offers a diverse range of products designed to enhance cycling performance and data analysis. Its offerings include the iSport, a wireless cycling computer and power meter; iPro, which aids in tracking and analyzing rides; iBike POWERHOUSE, a computer that adjusts to exercise goals; and iAero, which assists with power and wind tunnel measurements. Additionally, Velocomp provides various cycling computers such as the iDash CC, iDash CC Deluxe, and iDash +Power, along with protective cases and mounts for iPhone and iPod touch. The company's products are distributed through a network of dealers across multiple states in the United States.

Zixi

Venture Round in 2011
Zixi, LLC is a technology company that specializes in providing mobile, cloud-based, and on-premise solutions for the delivery of broadcast-quality HD video over the Internet and various networks. Founded in 2006 and headquartered in Waltham, Massachusetts, Zixi offers the Zixi Video Transport Platform, which serves a wide range of clients, including broadcasters, enterprises, and OTT video providers. The platform ensures real-time, high-quality streaming for live and on-demand video content, enhancing user experiences while significantly reducing operational costs. Zixi's services encompass various applications such as content contribution, news gathering, live sports events, virtual field trips, and educational broadcasts. Additionally, the company provides tools for managing and monitoring live broadcasts through its ZEN Management platform. With strategic alliances and a focus on transforming traditional broadcasting methods into more flexible, cost-effective operations, Zixi positions itself as a leader in the video delivery sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.